Cytek BiosciencesCTKB
About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Employees: 648
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
36% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 42
21% more capital invested
Capital invested by funds: $415M [Q3] → $501M (+$85.9M) [Q4]
11% more funds holding
Funds holding: 136 [Q3] → 151 (+15) [Q4]
2.96% more ownership
Funds ownership: 57.0% [Q3] → 59.95% (+2.96%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target | 62%upside $6 | Overweight Reiterated | 19 Mar 2025 |
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target | 116%upside $8 | Overweight Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 3 articles about CTKB published over the past 30 days
